By Colin Kellaher
Galapagos's number-two executive, Thad Huston, is leaving the biotechnology company after just over two years on the job.
Galapagos on Tuesday said Huston, who joined the Belgium-based company in July 2023 as chief operating and financial officer from Gilead's Kite Pharma unit, plans to depart effective Aug. 1 to return to the U.S. for personal and professional reasons.
The company said it expects to announce Huston's successor in the coming months.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 15, 2025 06:06 ET (10:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.